China Fall Dampens GSK’s Emerging Markets Business
This article was originally published in PharmAsia News
Executive Summary
GSK's emerging markets sales have again been hit by rising competition and the ongoing restructuring of its China business, but CEO Witty sees the dip as "reasonably temporary" and expects improvements in the fourth quarter.